Notice Type
Departmental
Notice Title

Provisional Consent to the Distribution of New Medicines

Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product: Aspen Codeine
Active Ingredient: Codeine phosphate hemihydrate 30mg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Aspen Pharma Pty Limited, Dandenong South, Australia


Note:
This consent is given subject to the following condition:

The medicine may only be marketed or distributed when no other codeine phosphate medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet PHARMAC tender obligations.

Note: This consent is valid for two years from the date of publication of this notice.

Product: Aspen Dexamfetamine
Active Ingredient: Dexamfetamine sulfate 5mg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Aspen Pharma Pty Limited, Dandenong South, Australia


Note:
This consent is given subject to the following condition:

The medicine may only be marketed or distributed when no other dexamfetamine medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet PHARMAC tender obligations.

Note: This consent is valid for two years from the date of publication of this notice.

Product: Nadolol BNM
Active Ingredient: Nadolol 40mg
Dosage Form: Tablet
New Zealand Sponsor: Boucher & Muir (New Zealand) Limited t/a BNM Group
Manufacturer: Zenara Pharma Pvt. Limited, Hyderabad, India


Note:
This consent is given subject to the following condition:

The medicine may only be marketed or distributed when no other nadolol medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet PHARMAC tender obligations.

Note: This consent is valid for two years from the date of publication of this notice.

Product: Nadolol BNM
Active Ingredient: Nadolol 80mg
Dosage Form: Tablet
New Zealand Sponsor: Boucher & Muir (New Zealand) Limited t/a BNM Group
Manufacturer: Zenara Pharma Pvt. Limited, Hyderabad, India


Note:
This consent is given subject to the following condition:

The medicine may only be marketed or distributed when no other nadolol medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet PHARMAC tender obligations.

Note: This consent is valid for two years from the date of publication of this notice.

Dated this 10th day of October 2022.

MATTHEW SPENCER, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).